12 results about "Thrombotic disorder" patented technology

The present disclosure relates to a method for treating or preventing a thrombotic disorder, comprising administering to a subject in need thereof an effective amount of the Compound (1) or a pharmaceutically acceptable salt thereof, at a dose in the range of 0.01-0.3 mg / kg, inclusive. The present disclosure further relates to compositions for use in such a method.

The present disclosure refers to 5-amino-2,3-dihydro-1,4-phthalazinedione and its pharmaceutically acceptable salts for the prophylaxis or treatment of thrombotic disorders. The invention relates in particular to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Pharmaceutical compositions, advantageous formulation techniques and a method of treatment are disclosed.

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

The present invention provides engineered plasmin variants and related compositions that are resistant to inhibition of plasmin protease activities by plasmin inhibitors, which can be used as direct-acting thrombolytic agents in the treatment of thrombosis and thrombotic disorders.

The present disclosure refers to 5-amino-2,3-dihydro-1,4-phthalazinedione and its pharmaceutically acceptable salts for the prophylaxis or treatment of thrombotic disorders. The invention relates in particular to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Pharmaceutical compositions, advantageous formulation techniques and a method of treatment are disclosed.

The present disclosure relates to methods for treating or preventing a thrombotic disorder in a subject in need thereof, comprising administering to the subject in need thereof a therapeutically effective amount of zalunfiban, or a pharmaceutically acceptable salt thereof, wherein the subject has renal impairment.

The present invention relates to the field of standardized identification technology, and more specifically, to a method and system for cardiovascular disease identification based on medical insurance data. The scheme includes obtaining a medical insurance database, storing the information as a medical insurance data group according to the time of information entry; setting a standard name dictionary including heart failure, heart failure, ischemic heart disease or coronary heart disease, valvular heart disease, arrhythmia, thrombotic disease, peripheral vascular disease, cerebrovascular disease, pulmonary vascular disease, hypertension and aortic aneurysm according to the relevant disease diagnosis names; performing keyword matching, similarity analysis and matching according to the standard name dictionary and the medical insurance data group, and forming a standard classification list with the third standard dictionary; storing and displaying according to the standard classification list. After obtaining the medical insurance data, the scheme performs a three-level similarity analysis according to the standard diagnosis name, completes multiple diagnostic dictionary updates, and forms a standardized identification method that is highly efficient and suitable for practical applications.

The invention concerns compositions and methods for treating protein C deficiency comprising adeno associated virus (AAV) vectors comprising a nucleic acid sequence encoding protein C (AAV -PC). The invention further provides non-human animal models for screening and assessing the efficacy of potential therapeutic agents for treating pro- thrombotic disorders, such as protein C deficiency.

The present disclosure relates to 5-amino-2, 3-dihydro-1, 4-phthalazindiones and pharmaceutically acceptable salts thereof for use in the prevention or treatment of thrombotic disorders. In particular, the invention relates to the use of a sodium salt of 5-amino-2, 3-dihydro-1, 4-phthalazindione for this purpose. Pharmaceutical compositions, advantageous techniques of formulation, and methods of treatment are disclosed.

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

The invention discloses an application of 4-octyl itaconic acid in preparation of a medicine for preventing and / or treating thrombotic diseases. A large number of experiments prove that 4-octyl itaconic acid can prevent and treat thrombus induced by carrageenan and relieve endothelial injury caused by endotoxin, expression of adhesion factors and inflammatory factors in endothelial cells and generation of active oxygen can be reduced, and the 4-octyl itaconic acid is small in drug toxicity, high in safety and free of toxic and side effects. The compound has a wide application prospect in clinical prevention and treatment of thrombotic diseases.